Trevogrumab combined with Wegovy helps preserve lean mass
Healio reports on the phase 2 COURAGE trial, presented at the European Association for the Study of Diabetes meeting and funded by Regeneron. In 599 adults with obesity, adding trevogrumab to semaglutide (Wegovy) cut 26-week lean mass loss to 1.6 kg or 1.9 kg versus 3.4 kg with semaglutide alone. A triple combination with garetosmab-grts raised safety concerns, including two deaths, and Regeneron won't advance it.
Why it matters: Relevant to adults with obesity considering medical weight loss, and the clinicians who refer them, who follow mid-stage research on muscle loss during semaglutide treatment.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to healio.com. October 5, 2026.